SSRP1 and cancer: Similar to Olaparib, CBL0137 pre-treatment (24 h) significantly sensitized HR-proficient and SSRP1-high OVCAR-8 and OVCAR-4 cells as well as HR-deficient SSRP1-high PEO1 cells to another PARPi, Rucaparib (Additional file 2, Fig. S6A, B), suggesting that observed synergistic anti-cancer activity of CBL0137 in SSRP1-high HGSCs is relevant to a number of clinically approved PARPi.